2015, Competition and Pharmacology

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2015

Competition

Pharmacology

Patents: a necessary evil?

European Pharmaceutical Review

OCTOBER 19, 2022

2 Recently, the US Patent and Trademark Office (US PTO) reiterated the concern that patents have been “misused to inhibit and delay – for years and even decades – competition from generic drugs and biosimilars, denying Americans access to lower-cost drugs.” Patents are often described as the ‘lifeblood’ of pharmaceutical companies.

Food and Drug Administration

Food and Drug Administration Pharmaceutical products Pharmaceutical FDA

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

JANUARY 16, 2023

Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. And all are predominantly prevented or treated with medicines that are decades old. About the author.

FDA

FDA Healthcare Healthcare Medicine

Webinars

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

MORE WEBINARS

Pharma Rep Focus

Patents: a necessary evil?

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

Webinars

Stay Connected